Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors

• DOI: 10.1186/s12913-021-06827-0
• Publication Date: 2021-08-13T01:02:33Z
• Authors: Yun Bao; Bei Gao; Min Meng; Bin Ge; Yan Yang; Chunchun Ding; Bingyin Shi; Limin Tian
• Keywords: Linagliptin

Abstract Background Medicine purchasing in Chinese public hospitals is decided by the hospital Pharmacy Management Committee (PMC), that complex, subjective and requires efficient approaches to ensure transparency consistency for factors being considered. This study aimed use Evidence Value: Impact on Decision Making (EVIDEM) framework assess medicine these hospitals. In this anti-diabetic drugs DPP-4 inhibitors, which work inhibiting activation of Dipeptidyl Peptidase 4 (DPP-4) were appraised. Methods Following EVIDEM methodology (EVIDEM-10th), we convened an appraisal group asked each individual express their perspectives assigning weights criterion. A systematic literature search information criterion five inhibitors was completed. Then scored inhibitors. The estimated value obtained Multi-Criteria Analysis (MCDA) combined weighting with scoring intervention Results By weights, most important quality evidence (4.01±0.52), comparative cost consequences-non-medical least (2.87±1.03). Criteria included disease severity, size affected population, effectiveness, type therapeutic/preventive benefit intervention, all assigned same weight 3.58. After MCDA, overall orders inhibitor Sitagliptin (0.45), Linagliptin (0.44), Vildagliptin (0.43), Alogliptin (0.42) Saxagliptin (0.40). Conclusions Based found similar. It feasible MCDA